Efficacy and Effect — Within the Approved Scope— The boundary of the package insert, and the traps of implication and suggestion

01Why "within the approved scope" is the starting point of everything

Material review surfaces every conceivable issue. Expression exaggeration, chart axes, safety-information balance, citation appropriateness, comparator selection, media-specific nuances. Countless. Yet 70% of all of these collapse into one question: "is this exceeding the approved scope?"

Three reasons.

• Legal reach: the core of "exaggerated advertising" under Pharmaceutical Act §66 is expressions about efficacy and effect (see Ad Regulations 01)
• Impact on prescribing: clinician prescribing starts from the package insert's efficacy/effect. If a material hints at scope-beyond, it directly bends prescribing
• Impact on patients: when patient-facing material hints at scope-beyond, it manufactures false expectation of "this will cure me"

"Expressing within the approved scope" is the most basic restraint a pharma company exercises in its market communication. The moment that breaks, the precondition of the credence-good business collapses.

02How to read the "efficacy / effect" section of the package insert

The "efficacy / effect" section of a package insert (PI) is exactly the wording approved by the Minister of Health, Labour and Welfare. Material expressions must not exceed it. Obvious in principle, but in practice "exceeded without realizing" happens constantly.

Three points to read carefully.

Point 1 — name of the indication

If "hypertension" is written, then "a drug that controls blood pressure," "useful for pre-hypertension," "for those concerned about their blood pressure" — all of these are outside. Approval is for the diagnosis "hypertension." It does not extend to upstream conditions (pre-hypertension) or peripheral ones (concerned individuals).

Point 2 — the premise of dosage and administration

Efficacy is inseparable from dosage. If the dosage reads "adults, once daily X mg orally," the effect at that dosage is the scope. Changing the dose, changing the route, extending the period — each is outside.

Point 3 — precautions related to efficacy

Often, under the efficacy section, there is "precautions related to efficacy and effect" — listing patient limits, initiation criteria, combination conditions. That too is part of efficacy — part of what must be honored.

When making a material, put these three sections of the PI in front of you, in their original form. From that anchor, audit every expression.

03The boundary of "implication" — §66's "implicit" wording

Pharmaceutical Act §66 prohibits exaggerated expressions "whether explicit or implicit". Even if you do not directly write "it cures X," if the impression "it seems to cure X" lingers in the reader's mind, that is a violation.

What counts as "implication" or "suggestion"? Five patterns the field repeatedly catches:

• Listing peripheral symptoms: enumerating symptoms adjacent to the indication so the product seems "likely to work"
• Out-of-context citation: citing a result from outside the approved scope, separated from its context
• Use-scene scripting: in patient material, presenting "in times like this you might want it" — scenes outside the approved indication
• Comparative superiority hint: implying comparison with competitors or alternatives, and through that, suggesting off-label
• Paraphrasing the technical: when translating medical language to plain language, loosening the definition and broadening the scope

Common thread: "no explicit deviation, but the post-read impression lands outside the approved scope." The reviewer's eye looks not at the literal text but at what remains in the clinician's or patient's head after reading.

04Traps of "almost," "feel," "expected"

As classic implications, three Japanese-equivalent expressions deserve special attention. Each has its own trap.

The "almost" trap

The "feel" trap

The "expected" trap

05Auditing the scope in four layers

Make a habit of running through four layers in order. Once embodied, judgment speed jumps.

Of the four, the most overlooked in the field is L3 (target-patient limits). A material may say "for patients with X," yet the PI may add "limited to adults with severity ≥ X." Making L3 a routine question is the shortcut to not getting hit at internal review.

06Case studies — five typical deviations

Case A — expanding the indication to "pre-conditions"

NG: "Effects of this drug, together with lifestyle change, can be expected even in pre-hypertension."

PI indication: "hypertension." Pre-condition (borderline) is out of scope. "Can be expected" implicit + L1 deviation — double violation.

Case B — hinting at extended dosing period

NG: "Improvement at 12 weeks → further stabilization can be expected with continued administration."

If the pivotal trial only went to 12 weeks, effects beyond are not in the PI. L2 dosage deviation.

Case C — comprehensive appeal via peripheral symptoms

NG: "For those troubled by insomnia, fatigue, lack of concentration."

If the indication is "depression," singling out only "insomnia" and "fatigue" — partial symptoms — creates the impression these are standalone indications. L1 + L4 mixed violation.

Case D — implying indication via comparison to other drugs

NG: "In cases unresponsive to other drugs, this drug was effective."

"Cases unresponsive to other drugs" is not written as an approved condition in the PI (except in specific guideline-permitted refractory cases). The comparison implicitly fabricates a "refractory indication." L3 deviation.

Case E — "use scene" in patient material

NG: "When the tension before an exam is too much, this drug can help."

Even if the indication is "anxiety disorder," presenting a scenario like "tension before an exam" implies the indication extends into ordinary life tension. L1 + L4 violation.

07Three questions when judgment wobbles

Boundary judgments don't always settle uniquely. In gray zones, ask three questions in order.

1. "Would a clinician reading this be tempted to use the drug beyond the PI's efficacy/effect section?" — YES = NG. NO = the implication is weak
2. "Would a patient reading this expect 'maybe it works' even when they are outside the indication?" — YES = NG
3. "If PMDA or MHLW examined this expression, which line of the PI could be cited as the basis for OK?" — if no line can be pointed to, NG

If you cannot answer all three with a clear NO or a cited line, the expression is high risk. The very act of "judgment wobbling" is an indicator of weak expression.

08Three habits for tomorrow

1. When reading a material, place the original PI "efficacy / effect" section in front of you first — don't rely on memory or summary. Don't skip the cost of checking the original every time
2. Search "almost," "feel," "expected" mechanically (Find/Replace) — typical implicit words are machine-detectable. Let AI handle the first-pass screen
3. Every time you issue a NO, also produce an alternative with a PI citation — don't end on NO. Present the rewrite as a set. This changes the quality of dialogue with the field